Nordic News and Business Promotion in Asia
A Chinese drugmaker applied for approval on 3 April 2024 to sell their biosimilar Ozempic drug in China. This potentially challenges the expansion plans of Novo Nordisk in China, who …
Chinese drugmaker seeks approval of Ozempic-like drug Read More
The Chinese version of the Novo Nordisk Semaglutide injection Wegovy has gotten the green light to begin clinical trials for weight loss treatment. The drug is developed by CSPC Pharmaceutical …
Chinese version of Novo Nordisk drug gets green light Read More
The Danish pharmaceutical company Novo Nordisk boosts its production in China by investing around US$ 556 million in its Chinese flagship factory in Tianjin. The sterile preparation expansion project has …
Novo Nordisk boosts drug production in China Read More
The Danish healthcare company Novo Nordisk expects China to approve their popular weight-loss drug, Wegovy, for sale this year. The company will initially focus on patient paying out-of-pocket for the …
Novo Nordisk expects China to approve Wegovy Read More
Novo Nordisk has established itself in the medicine market with patents that earn billions. Mainly due to the obesity drug Wegovy and the diabetes medicine Ozempic. Both consists of an …
Approaching patent expiration in China may threaten Novo’s billion-dollar business Read More
Danish pharmaceutical company Novo Nordisk has surpassed LVMH and is now Europe’s most valuable listed company. LVMH, the world’s biggest luxury retailer, is currently suffering due to growing concerns about …
Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company Read More
Danish pharmaceutical company Novo Nordisk has achieved the highest year-on-year revenue growth by sales during the second quarter of 2023 – in comparison to the other 20 top pharmaceutical firms, …
Novo Nordisk in record growth due to obesity and diabetes drug sales Read More
Novo Nordisk’s obesity medicine Wegovy reduces the risk of heart attacks and strokes according to a highly anticipated study. People with obesity or are overweight with a history of heart …
Novo Nordisk is now second biggest firm in Europe after study finds that Wegovy cuts risk of heart attacks Read More
Danish pharmaceutical titan Novo Nordisk has applied to China’s drug regulator to widen the range of use of its diabetes medicine Ozempic. In the US Ozempic is also used as …
Novo Nordisk’s diet drug may land in China soon Read More
Danish Novo Nordisk reported Thursday, May 4, a 39% increase in first-quarter profits, due to the company’s sales of obesity treatments. From January to March, net profit reached 19.8 billion …
Novo Nordisk experience big profit rise due to obesity treatments Read More